← Patent-cliff monitor small molecule ELUCIREM GADOPICLENOL
Loss of exclusivity January 2040 latest FDA-listed patent expiry
Company Guerbet → See this company's full patent-cliff portfolio Drug detail Brand name ELUCIREM Active ingredient GADOPICLENOL Strength 7.2765GM/15ML (485.1MG/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval September 2022 Marketing status RX
Listed patents Patent Expires Type 12064487 January 2040 use U-4424 11590246 January 2040 product 10973934 August 2039 substance 8114863 May 2032 substance, product
Regulatory exclusivity Code Expires NPP February 2029 NCE September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.